Clinical Trials
87
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials
Proof of Concept Study on BP1.4979 Effect on Essential Tremor
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 50
- Registration Number
- NCT07074002
- Locations
- 🇫🇷
CHU de Lille - Hôpital Roger SALENGRO, Lille, France
Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation
- Conditions
- Premature (Early) Ejaculation
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 60
- Registration Number
- NCT07047404
- Locations
- 🇫🇷
University Hospital of Nîmes, Nîmes, France
Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents
- Conditions
- Autism Spectrum Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 62
- Registration Number
- NCT05953389
- Locations
- 🇫🇷
Centre Hospitalier Charles Perrens, Bordeaux, France
🇫🇷Nantes University Hospital, Nantes, France
🇫🇷CH le Rouvray, Sotteville-lès-Rouen, France
Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke
- Conditions
- Fatigue
- Interventions
- Drug: BP1.3656
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 5
- Registration Number
- NCT05240560
- Locations
- 🇫🇷
Hôpital Pellegrin - CHU BORDEAUX, Bordeaux, France
🇨🇭Inselspital Berne, Berne, Switzerland
Pilot Study on BP1.4979 Effect on Binge Eating Disorders
- Conditions
- Binge-Eating Disorder
- Interventions
- Drug: BP1.4979 active drugDrug: Placebo
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 66
- Registration Number
- NCT05118906
- Locations
- 🇫🇷
Nutrition Department, La Pitié Salpêtrière Hospital, Paris, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Harmony Biosciences Secures Patent Protection for WAKIX Through 2030 Settlement with Lupin
Harmony Biosciences reached a settlement agreement with Lupin Limited that prevents generic competition for WAKIX until January 2030, strengthening the company's intellectual property position for its narcolepsy treatment.
FDA Issues Refusal to File for Pitolisant in Idiopathic Hypersomnia Treatment
Harmony Biosciences receives FDA Refusal to File letter for pitolisant's supplemental New Drug Application in adult idiopathic hypersomnia patients with excessive daytime sleepiness.